Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company that specializes in developing proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's primary product, Lenzilumab, targets and neutralizes granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I dose escalation phase for multiple hematologic malignancies, and HGEN005, an anti-EMR1 monoclonal antibody in pre-clinical development for eosinophilic diseases. The company is engaged in collaborations to advance its research, including a partnership with Kite Pharma for a multi-center study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma, as well as a cooperative agreement with the Department of Defense for potential COVID-19 treatment applications. Founded in 2000 and based in Burlingame, California, Humanigen was previously known as KaloBios Pharmaceuticals before rebranding in 2017.